Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Investigating signalling changes leading to recurrence in matched primary and recurrent pairs of glioblastoma brain tumour stem cells

EF 2020-21

Résumé
Glioblastoma (GBM) is the most common primary brain tumour in adults. High invasiveness, aggressive growth, and recurrence make GBM difficult to treat. Despite the current standard of care, GBM has a median overall survival of a mere 15 months after diagnosis. Based on the poor prognosis, there is a dire need for new treatments for GBM. Cancer stem cells, a sub-population of cells found in many different cancers, have the ability to self-renew and differentiate into the heterogeneous population of cells that make up the bulk of a tumour. In GBM, brain tumour stem cells (BTSCs) are considered one of the primary causes for treatment resistance and high rates of recurrence. The process of tumour recurrence is vastly understudied in BTSCs and has never been fully examined in matching primary and recurrent pairs of BTSCs from the same patients. Only a few matching BTSC primary/recurrent pairs exist in North America. Our lab has BTSCs generated from single patient's primary tumour and the matching recurrent tumours. We will use the BTSCs from matched sets in order to examine signalling changes that occur in recurrent BTSCs. We will further investigate how those changes can be targeted or modulated in order to reduce the aggressive phenotype associated with recurrent tumours and revert it back to a more primary (less aggressive) phenotype. Modulating the matching primary and recurrent BTSCs to change their growth, migratory, and tumour producing phenotypes into each other using genetic or pharmacological means has never been done before. This project will help identify important mechanisms in BTSCs that contribute to GBM recurrence. This, in turn, could lead to new treatments for recurrent GBM and hopefully improve the overall survival for this devastating disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449795
Name
Heemskerk Kyle M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating signalling changes leading to recurrence in matched primary and recurrent pairs of glioblastoma brain tumour stem cells
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Brain Tumour Stem Cells; Glioblastoma; Matched Pairs; Recurrence; Signalling Pathways
Abstract
Glioblastoma (GBM) is the most common primary brain tumour in adults. High invasiveness, aggressive growth, and recurrence make GBM difficult to treat. Despite the current standard of care, GBM has a median overall survival of a mere 15 months after diagnosis. Based on the poor prognosis, there is a dire need for new treatments for GBM. Cancer stem cells, a sub-population of cells found in many different cancers, have the ability to self-renew and differentiate into the heterogeneous population of cells that make up the bulk of a tumour. In GBM, brain tumour stem cells (BTSCs) are considered one of the primary causes for treatment resistance and high rates of recurrence. The process of tumour recurrence is vastly understudied in BTSCs and has never been fully examined in matching primary and recurrent pairs of BTSCs from the same patients. Only a few matching BTSC primary/recurrent pairs exist in North America. Our lab has BTSCs generated from single patient's primary tumour and the matching recurrent tumours. We will use the BTSCs from matched sets in order to examine signalling changes that occur in recurrent BTSCs. We will further investigate how those changes can be targeted or modulated in order to reduce the aggressive phenotype associated with recurrent tumours and revert it back to a more primary (less aggressive) phenotype. Modulating the matching primary and recurrent BTSCs to change their growth, migratory, and tumour producing phenotypes into each other using genetic or pharmacological means has never been done before. This project will help identify important mechanisms in BTSCs that contribute to GBM recurrence. This, in turn, could lead to new treatments for recurrent GBM and hopefully improve the overall survival for this devastating disease.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Heemskerk, Kyle M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~